Scholarlink

Purpose of Review <p>This article provides an updated review of the pathophysiology, risk factors, outcomes, and treatment options for stress cardiomyopathy, also known as Takotsubo syndrome (TTS), in patients with cancer.</p> Recent Findings <p>Patients with malignancy have increased susceptibility to TTS due to cancer-related physiological stressors (surgery, cancer therapies, and infection) and emotional triggers. Anticancer drugs most associated with TTS include fluoropyrimidines, angiogenesis inhibitors, and immune checkpoint inhibitors. Cancer influences the clinical course and outcomes of TTS. Treatment focuses on stabilizing hemodynamics, providing supportive care, and using pharmacologic interventions to reduce catecholamine excess and support myocardial recovery.</p> Summary <p>Expert consensus is to hold cancer treatment, even if temporarily, in cases of severe LV dysfunction (ejection fraction [EF] &lt; 35%), cardiogenic shock, or life-threatening arrhythmia. Decisions about holding or resuming cancer therapy should be individualized, highlighting the importance of close coordination between oncologists and cardiologists.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Stress Cardiomyopathy Syndromes in Cardio-Oncology

  • 期刊论文

  • 发表日期：

    2025年9月4日

查看全文
  • Siddhant Passey,
  • Shea-Lee Godin,
  • Abhigna Kolupoti,
  • Nawreen Nusrat Quazi,
  • Agnes S. Kim

摘要

Purpose of Review

This article provides an updated review of the pathophysiology, risk factors, outcomes, and treatment options for stress cardiomyopathy, also known as Takotsubo syndrome (TTS), in patients with cancer.

Recent Findings

Patients with malignancy have increased susceptibility to TTS due to cancer-related physiological stressors (surgery, cancer therapies, and infection) and emotional triggers. Anticancer drugs most associated with TTS include fluoropyrimidines, angiogenesis inhibitors, and immune checkpoint inhibitors. Cancer influences the clinical course and outcomes of TTS. Treatment focuses on stabilizing hemodynamics, providing supportive care, and using pharmacologic interventions to reduce catecholamine excess and support myocardial recovery.

Summary

Expert consensus is to hold cancer treatment, even if temporarily, in cases of severe LV dysfunction (ejection fraction [EF] < 35%), cardiogenic shock, or life-threatening arrhythmia. Decisions about holding or resuming cancer therapy should be individualized, highlighting the importance of close coordination between oncologists and cardiologists.